Data from: Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice

Fig1AThis data file is associated with Fig1A of the accompanied publication. Survival data of bone marrow only, vehicle treated, and Ibrutinib treated recipients. Column A is an arbitrary identification number given to each mouse. Column B indicates the time-point at which a survival (marked as "0') or non-survival event (marked as "1") occurred. Column C indicates the bone marrow alone group. Column D indicates mice treated with vehicle. Column E indicates mice treated with Ibrutinib 10mg/kg. Any other relevant information, including experimental conditions and setup is detailed in the accompanied publication.Fig1BThis data file is associated with Fig1B of the accompanied publication. Urine protein measurement data of bone marrow only, vehicle treated, and Ibrutinib treated recipients. Column A is an arbitrary identification number given to each mouse. Column B indicates the time-point at which a non-proteinuria event (marked as "0') or a proteinuria event (marked as "1") occurred. Proteinuria event "1" is defined as a mouse showing a >2,000mg/dL score using Albustix urine test strips.Column C indicates the vehicle group, Column D indicates mice treated with Ibrutinib 10mg/kg. Column E indicates mice treated with Ibrutinib 15mg/kg, Column F indicates bone marrow alone mice treated with phosphate buffered saline, Column G indicates bone marrow alone mice treated with vehicle, Column H indicates bone marrow alone mice treated with 10mg/kg Ibrutinib. Any other relevant information, including experimental conditions and setup is detailed in the accompanied publication.Fig1CThis data file is associated with Fig1C of the accompanied publication. Survival data of bone marrow only, vehicle treated, and Ibrutinib treated recipients. Column A is an arbitrary identification number given to each mouse. Column B indicates the time-point at which a survival (marked as "0') or non-survival event (marked as "1") occurred. Column C indicates the bone marrow alone group. Column D indicates mice treated with vehicle. Column E indicates mice treated with Ibrutinib 10mg/kg. Column F indicates mice treated with 10mg/kg Ibrutinib beginning 14 days post transplantation. Any other relevant information, including experimental conditions and setup is detailed in the accompanied publication.Fig1DThis data file is associated with Fig1D of the accompanied publication. Urine protein measurement data of bone marrow only, vehicle treated, and Ibrutinib treated recipients. Column A is an arbitrary identification number given to each mouse. Column B indicates the time-point at which a non-proteinuria event (marked as "0') or a proteinuria event (marked as "1") occurred. Proteinuria event "1" is defined as a mouse showing a >2,000mg/dL score using Albustix urine test strips.Column C indicates the BM only group, Column D indicates mice treated with vehicle. Column E indicates mice treated with Ibrutinib 10mg/kg beginning 7 days post-transplant, Column F indicates mice treated with 10mg/kg Ibrutinib beginning 14 days post-transplant. Any other relevant information, including experimental conditions and setup is detailed in the accompanied publication.Fig2AThis data file is associated with Fig2A of the accompanied publication. Each panel is a representative histogram of one mouse from each group. Mice treated with either vehicle or 10mg/kg Ibrutinib were injected with 40 x 10^6 CD25 depleted CFSE labeled whole splenocytes. Flow cytometry readings from recipients were taken 4 days post-transplant. Any other relevant information including experimental conditions and setup are included in the accompanied publication.Fig2BThis data file is associated with Fig2B of the accompanied publication. Mice treated with either vehicle or 10mg/kg Ibrutinib were injected with 40 x 10^6 CD25 depleted CFSE labeled whole splenocytes. Flow cytometry readings from recipients were taken 4 days post-transplant. Using the percentage of CFSE diluted or CFSE low, the amount of proliferated cells can be determined. Column and row labels are self-explanatory. Any other relevant information including experimental conditions and setup are included in the accompanied publication.Fig2CThis data file is associated with Fig2C of the accompanied publication. Mice treated with either vehicle or 10mg/kg Ibrutinib were injected with 40 x 10^6 CD25 depleted CFSE labeled whole splenocytes. Flow cytometry readings from recipients were taken 4 days post-transplant. The amount of CD40,80, and 86 on donor B cells was analyzed. Column and row labels are self-explanatory. Value from Column "E" row "2" was excluded as an extreme outlier compared to other values within the same group. Any other relevant information including experimental conditions and setup are included in the accompanied publication.Fig2DThis data file is associated with Fig2D of the accompanied publication. Mice treated with either vehicle or 10mg/kg Ibrutinib were injected with 40 x 10^6 CD25 depleted whole splenocytes. Peripheral blood was collected from each recipient and serum was taken for ELISA measurement of total IgG and IgG2a autoantibodies. Each value represents the reported optical density (OD) output of an ELISA plate-reader. Column and row labels are self-explanatory. Any other relevant information including experimental conditions and setup are included in the accompanied publication.Fig3AThis data file is associated with Fig3A of the accompanied publication. Urine protein measurement data of no injection, vehicle treated, and Ibrutinib treated recipients. Column A indicates the time-point at which urine protein measurements were taken post-transplant using Albustix urine test strips. Column and row labels are self-explanatory. Any other relevant information, including experimental conditions and setup is detailed in the accompanied publication.Fig3BThis data file is associated with Fig3B of the accompanied publication. Mice treated with no injection, vehicle, or 10mg/kg Ibrutinib were injected with 80-100 x 10^6 whole splenocytes. Peripheral blood was collected from each recipient and serum was taken for ELISA measurement of total IgG and IgG2a autoantibodies. Each value represents the reported optical density (OD) output of an ELISA plate-reader. Column A indicates the number of weeks post-transplant serum samples was taken. Additional Column and row labels are self-explanatory. Any other relevant information including experimental conditions and setup are included in the accompanied publication.Fig3CThis data file is associated with Fig3C of the accompanied publication. Mice treated with no injection, vehicle, or 10mg/kg Ibrutinib were injected with 80-100 x 10^6 whole splenocytes. Peripheral blood was collected from each recipient and serum was taken for ELISA measurement of total IgG and IgG2a autoantibodies. Each value represents the reported optical density (OD) output of an ELISA plate-reader. Column A indicates the number of weeks post-transplant serum samples was taken. Additional Column and row labels are self-explanatory. Any other relevant information including experimental conditions and setup are included in the accompanied publication.Fig4AThis data file is associated with Fig4A of the accompanied publication. Mice treated with BM alone, vehicle, or 10mg/kg Ibrutinib were injected with 5 x 10^6 whole splenocytes. Clinical scores representing 6 visible factors were recorded and tabulated once per week following Day 14 post-transplant. Column A represents the day post-transplant the scoring was conducted on. Additional column and row titles are self-explanatory. Any other relevant information including experimental conditions and setup are included in the accompanied publication.Fig4B imagesThis data file is associated with Fig4B of the accompanied publication. Mice treated with BM alone, vehicle, 5mg/kg, or 10mg/kg Ibrutinib were injected with 5 x 10^6 whole splenocytes. Skin lesions from each recipient were excised after euthanasia and subjected to H&E staining for scoring by a professional pathologist. Representative microscope images were taken from one mouse from each group. #199 is from BM alone group, #202 is from vehicle treated group, #205 is from 10mg/kg Ibrutinib treated group, #211 is from 5mg/kg Ibrutinib treated group. Any other relevant information including experimental conditions and setup are included in the accompanied publication.Fig4C imagesThis data file is associated with Fig4C of the accompanied publication. Mice treated with BM alone, vehicle, or 10mg/kg Ibrutinib were injected with 5 x 10^6 whole splenocytes. Representative images were taken of one mouse from each group using a typical smartphone on Day 41 post-transplant. The file name of each representative image indicates the group that the mouse belongs in and should be self-explanatory. Any other relevant information including experimental conditions and setup are included in the accompanied publication.Fig4DThis data file is associated with Fig4D of the accompanied publication. Mice treated with BM alone, vehicle, or 10mg/kg Ibrutinib were injected with 5 x 10^6 whole splenocytes. Skin lesions from each recipient were excised after euthanasia and subjected to H&E staining for scoring by a professional pathologist. Skin sections were scored based on several criteria as described in the accompanied manuscript. Columns and row titles are self-explanatory. Any other relevant information including experimental conditions and setup are included in the accompanied publication.Fig4EThis data file is associated with Fig4E of the accompanied publication. Flow cytometry readings of B220 and CD138 were analyzed. B220low and CD138+ cell populations are indicative of autoantibody producing plasma cells. Columns and row titles are self-explanatory. Any relevant information for this figure, including experimental conditions and setup are included in the methods, results, or discussion section of the accompanied publication.Fig4FThis data file is associated with Fig4F of the accompanied publication. Flow cytometry of splenic CD4+PD-1+CXCR5+ cell populations was analyzed. CD4+PD-1+CXCR5+ cell populations are indicative of T-follicular helper (Tfh) cells. Any relevant information for this figure, including experimental conditions and setup are included in the methods, results, or discussion section of the accompanied publication.Fig4GThis data file is associated with Fig4G of the accompanied publication. Flow cytometry of B220+ B cells was analyzed. High B cell counts following transplantation are indicative of improved immune reconstitution and reduced GVHD pathogenesis. Any relevant information for this figure, including experimental conditions and setup are included in the methods, results, or discussion section of the accompanied publication.Fig4HThis data file is associated with Fig4H of the accompanied publication. Column and row labels are self-explanatory. Any relevant information for this figure, including experimental conditions and setup are included in the methods, results, or discussion section of the accompanied publication.Fig5AThis data file is associated with Fig5A of the accompanied publication. Survival of mice given 1-2 x 10^6 whole splenocytes. Column A is the mouse identification number. Column B is the time-point at which either a survival ("0") or non-survival ("1") event occurred. Other column and row titles should be self-explanatory. Mouse #482 was excluded from the results due to a non-GVHD related death confirmed by a DLAR veterinarian. Any relevant information for this figure, including experimental conditions and setup are included in the methods, results, or discussion section of the accompanied publication.Fig5BThis data file is associated with Fig5B of the accompanied publication. Clinical score of recipients given 1-2 x 10^6 whole splenocytes was monitored once per week following transplantation. Column A indicates time-point at which the clinical score was measured. Additional column and row titles are self-explanatory. Any relevant information for this figure, including experimental conditions and setup are included in the methods, results, or discussion section of the accompanied publication.Fig6AThis data file is associated with Fig6A of the accompanied publication. Survival of mice receiving 0.5-0.75 x 10^6 purified T cells. Column A indicates mouse identification number, Column B indicates time at which a non-survival ("1") or survival ("0") even occurred. Other columns and rows are self-explanatory. Any relevant information for this figure, including experimental conditions and setup are included in the methods, results, or discussion section of the accompanied publication.Fig6BThis data file is associated with Fig6B of the accompanied publication. Column A indicates time-point at which the clinical score was measured. Additional column and row titles are self-explanatory. Any relevant information for this figure, including experimental conditions and setup are included in the methods, results, or discussion section of the accompanied publication.Supplementary InformationThis data file is associated with all supplementary figures and information of the accompanied publication. This archive includes data files for S1_Fig, S2_Fig, S3_Fig, S4_Fig, S5_Fig. Individual data files of graphs or data within each supplementary figure (e.g., A in S1_Fig) are also included. Any relevant information for these figures, including experimental conditions and setup are included in the methods, results, or discussion section of the accompanied publication.

Fig1A 本数据文件对应随刊发表论文的图1A，包含仅骨髓移植组、赋形剂（vehicle）处理组及依鲁替尼（Ibrutinib）处理组受体小鼠的生存数据。A列为每只小鼠的随机识别编号；B列为生存事件（标记为“0”）或死亡事件（标记为“1”）发生的时间点；C列为仅骨髓移植组；D列为赋形剂处理组小鼠；E列为10mg/kg依鲁替尼处理组小鼠。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig1B 本数据文件对应随刊发表论文的图1B，包含仅骨髓移植组、赋形剂处理组及依鲁替尼处理组受体小鼠的尿蛋白检测数据。A列为每只小鼠的随机识别编号；B列为无蛋白尿事件（标记为“0”）或蛋白尿事件（标记为“1”）发生的时间点。其中蛋白尿事件“1”定义为使用Albustix尿液检测试纸条检测得到尿蛋白浓度>2000mg/dL的小鼠。C列为赋形剂组；D列为10mg/kg依鲁替尼处理组小鼠；E列为15mg/kg依鲁替尼处理组小鼠；F列为经磷酸盐缓冲液处理的仅骨髓移植组小鼠；G列为经赋形剂处理的仅骨髓移植组小鼠；H列为经10mg/kg依鲁替尼处理的仅骨髓移植组小鼠。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig1C 本数据文件对应随刊发表论文的图1C，包含仅骨髓移植组、赋形剂处理组及依鲁替尼处理组受体小鼠的生存数据。A列为每只小鼠的随机识别编号；B列为生存事件（标记为“0”）或死亡事件（标记为“1”）发生的时间点；C列为仅骨髓移植组；D列为赋形剂处理组小鼠；E列为10mg/kg依鲁替尼处理组小鼠；F列为移植后14天开始给予10mg/kg依鲁替尼处理的小鼠。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig1D 本数据文件对应随刊发表论文的图1D，包含仅骨髓移植组、赋形剂处理组及依鲁替尼处理组受体小鼠的尿蛋白检测数据。A列为每只小鼠的随机识别编号；B列为无蛋白尿事件（标记为“0”）或蛋白尿事件（标记为“1”）发生的时间点。其中蛋白尿事件“1”定义为使用Albustix尿液检测试纸条检测得到尿蛋白浓度>2000mg/dL的小鼠。C列为仅骨髓（BM）移植组；D列为赋形剂处理组小鼠；E列为移植后7天开始给予10mg/kg依鲁替尼处理的小鼠；F列为移植后14天开始给予10mg/kg依鲁替尼处理的小鼠。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig2A 本数据文件对应随刊发表论文的图2A，每组各取一只小鼠的代表性流式细胞术（flow cytometry）直方图。赋形剂处理组或10mg/kg依鲁替尼处理组小鼠均经尾静脉注射40×10^6个CD25缺失的CFSE标记全脾细胞。受体小鼠于移植后4天进行流式细胞术检测。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig2B 本数据文件对应随刊发表论文的图2B。赋形剂处理组或10mg/kg依鲁替尼处理组小鼠均经尾静脉注射40×10^6个CD25缺失的CFSE标记全脾细胞。受体小鼠于移植后4天进行流式细胞术检测。通过CFSE稀释或CFSE低表达细胞的占比，可计算增殖细胞的数量。行列标签含义自明。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig2C 本数据文件对应随刊发表论文的图2C。赋形剂处理组或10mg/kg依鲁替尼处理组小鼠均经尾静脉注射40×10^6个CD25缺失的CFSE标记全脾细胞。受体小鼠于移植后4天进行流式细胞术检测，分析供体B细胞表面CD40、CD80及CD86的表达量。行列标签含义自明。与同组其他数据相比，E列第2行的数值为极端异常值，已予以排除。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig2D 本数据文件对应随刊发表论文的图2D。赋形剂处理组或10mg/kg依鲁替尼处理组小鼠均经尾静脉注射40×10^6个CD25缺失的全脾细胞。采集每只受体小鼠的外周血，分离血清用于酶联免疫吸附测定（ELISA），检测总IgG及IgG2a自身抗体的水平。每个数值代表ELISA酶标仪读取的光密度（OD）输出值。行列标签含义自明。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig3A 本数据文件对应随刊发表论文的图3A，包含未注射组、赋形剂处理组及依鲁替尼处理组受体小鼠的尿蛋白检测数据。A列为移植后使用Albustix尿液检测试纸条进行尿蛋白检测的时间点。行列标签含义自明。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig3B 本数据文件对应随刊发表论文的图3B。未注射组、赋形剂处理组或10mg/kg依鲁替尼处理组小鼠均经尾静脉注射80~100×10^6个全脾细胞。采集每只受体小鼠的外周血，分离血清用于ELISA检测总IgG及IgG2a自身抗体的水平。每个数值代表ELISA酶标仪读取的光密度输出值。A列为采集血清样本的移植后周数。其余行列标签含义自明。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig3C 本数据文件对应随刊发表论文的图3C。未注射组、赋形剂处理组或10mg/kg依鲁替尼处理组小鼠均经尾静脉注射80~100×10^6个全脾细胞。采集每只受体小鼠的外周血，分离血清用于ELISA检测总IgG及IgG2a自身抗体的水平。每个数值代表ELISA酶标仪读取的光密度输出值。A列为采集血清样本的移植后周数。其余行列标签含义自明。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig4A 本数据文件对应随刊发表论文的图4A。仅骨髓移植组、赋形剂处理组或10mg/kg依鲁替尼处理组小鼠均经尾静脉注射5×10^6个全脾细胞。移植后14天起，每周记录并统计一次包含6项可见指标的临床评分。A列为进行评分的移植后天数。其余行列标签含义自明。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig4B images 本数据文件对应随刊发表论文的图4B。仅骨髓移植组、赋形剂处理组、5mg/kg依鲁替尼处理组或10mg/kg依鲁替尼处理组小鼠均经尾静脉注射5×10^6个全脾细胞。处死后采集每只受体小鼠的皮肤病灶组织，进行苏木精-伊红（H&E）染色，由专业病理学家进行评分。每组各取一只小鼠的代表性显微镜图像。其中#199来自仅骨髓移植组，#202来自赋形剂处理组，#205来自10mg/kg依鲁替尼处理组，#211来自5mg/kg依鲁替尼处理组。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig4C images 本数据文件对应随刊发表论文的图4C。仅骨髓移植组、赋形剂处理组或10mg/kg依鲁替尼处理组小鼠均经尾静脉注射5×10^6个全脾细胞。移植后第41天，使用普通智能手机拍摄每组各一只小鼠的代表性外观图像。每张代表性图像的文件名已标注小鼠所属组别，含义自明。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig4D 本数据文件对应随刊发表论文的图4D。仅骨髓移植组、赋形剂处理组或10mg/kg依鲁替尼处理组小鼠均经尾静脉注射5×10^6个全脾细胞。处死后采集每只受体小鼠的皮肤病灶组织，进行H&E染色，由专业病理学家进行评分。皮肤切片的评分依据随刊论文中描述的多项标准。行列标签含义自明。其余相关信息（包括实验条件与实验设置）详见随刊发表论文。
Fig4E 本数据文件对应随刊发表论文的图4E。对B220和CD138的流式细胞术检测结果进行分析。B220低表达且CD138阳性的细胞群为产生自身抗体的浆细胞。行列标签含义自明。本图的相关信息（包括实验条件与实验设置）详见随刊论文的方法、结果或讨论部分。
Fig4F 本数据文件对应随刊发表论文的图4F。对脾脏CD4+PD-1+CXCR5+细胞群的流式细胞术结果进行分析。CD4+PD-1+CXCR5+细胞群为滤泡辅助性T（Tfh）细胞。本图的相关信息（包括实验条件与实验设置）详见随刊论文的方法、结果或讨论部分。
Fig4G 本数据文件对应随刊发表论文的图4G。对B220阳性B细胞的流式细胞术结果进行分析。移植后高B细胞计数提示免疫重建良好及移植物抗宿主病（GVHD）发病风险降低。本图的相关信息（包括实验条件与实验设置）详见随刊论文的方法、结果或讨论部分。
Fig4H 本数据文件对应随刊发表论文的图4H。行列标签含义自明。本图的相关信息（包括实验条件与实验设置）详见随刊论文的方法、结果或讨论部分。
Fig5A 本数据文件对应随刊发表论文的图5A，包含输注1~2×10^6个全脾细胞的小鼠生存数据。A列为小鼠识别编号；B列为生存事件（标记为“0”）或死亡事件（标记为“1”）发生的时间点。其余行列标签含义自明。小鼠#482因经DLAR兽医确认的非移植物抗宿主病相关死亡，已从结果中排除。本图的相关信息（包括实验条件与实验设置）详见随刊论文的方法、结果或讨论部分。
Fig5B 本数据文件对应随刊发表论文的图5B。对输注1~2×10^6个全脾细胞的受体小鼠的临床评分进行每周一次的监测。A列为临床评分的测量时间点。其余行列标签含义自明。本图的相关信息（包括实验条件与实验设置）详见随刊论文的方法、结果或讨论部分。
Fig6A 本数据文件对应随刊发表论文的图6A，包含输注0.5~0.75×10^6个纯化T细胞的小鼠生存数据。A列为小鼠识别编号；B列为死亡事件（标记为“1”）或生存事件（标记为“0”）发生的时间点。其余行列标签含义自明。本图的相关信息（包括实验条件与实验设置）详见随刊论文的方法、结果或讨论部分。
Fig6B 本数据文件对应随刊发表论文的图6B。A列为临床评分的测量时间点。其余行列标签含义自明。本图的相关信息（包括实验条件与实验设置）详见随刊论文的方法、结果或讨论部分。
Supplementary Information 本数据文件对应随刊发表论文的所有补充图表及信息。本归档文件包含S1_Fig、S2_Fig、S3_Fig、S4_Fig、S5_Fig对应的数据文件，以及每张补充图表内的单张图表或数据对应的独立数据文件（如S1_Fig中的A部分）。本部分相关信息（包括实验条件与实验设置）详见随刊论文的方法、结果或讨论部分。